Literature DB >> 12595758

Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways.

P-L Kuo1, C-C Lin.   

Abstract

(-)-Epigallocatechin-3-gallate (EGCG) is a polyphenolic compound found in green tea. It has been reported to possess a wide range of pharmacological properties, and is one of the most promising chemopreventive agents for cancer. To provide a better understanding of the preventive effect of EGCG on liver cancer, we examined EGCG for its effect on proliferation and cell cycle progression in a human liver cancer cell line, Hep G2. The results showed that EGCG inhibited the proliferation of Hep G2 by inducing apoptosis and blocking cell cycle progression in the G1 phase. ELISA showed that EGCG significantly increased the expression of p53 and p21/WAF1 protein, and this contributed to cell cycle arrest. An enhancement in Fas/APO-1 and its two form ligands, membrane-bound Fas ligand (mFasL) and soluble Fas ligand (sFasL), as well as Bax protein, was responsible for the apoptotic effect induced by EGCG. Taken together, our study suggests that the induction of p53 and the activity of the Fas/FasL apoptotic system play major roles in the antiproliferative activity of EGCG in Hep G2 cells. Copyright 2003 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595758     DOI: 10.1007/bf02256057

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  35 in total

1.  Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.

Authors:  Dina Sabry; Omayma O Abdelaleem; Amani M El Amin Ali; Rehab A Mohammed; Nehal D Abdel-Hameed; Amira Hassouna; Warda A Khalifa
Journal:  Mol Biol Rep       Date:  2019-02-01       Impact factor: 2.316

Review 2.  Molecular and cellular targets.

Authors:  Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

3.  Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Authors:  Masood A Shammas; Paola Neri; Hemanta Koley; Ramesh B Batchu; Robert C Bertheau; Vidit Munshi; Rao Prabhala; Mariateresa Fulciniti; Yu Tzu Tai; Steven P Treon; Raj K Goyal; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway.

Authors:  Yuma Wada; Atsushi Takata; Tetsuya Ikemoto; Yuji Morine; Satoru Imura; Shuichi Iwahashi; Yu Saito; Mitsuo Shimada
Journal:  Surg Today       Date:  2019-02-07       Impact factor: 2.549

Review 5.  Targeting of histamine producing cells by EGCG: a green dart against inflammation?

Authors:  Esther Melgarejo; Miguel Angel Medina; Francisca Sánchez-Jiménez; José Luis Urdiales
Journal:  J Physiol Biochem       Date:  2010-07-22       Impact factor: 4.158

6.  Effect of Sinecatechins on HPV-Activated Cell Growth and Induction of Apoptosis.

Authors:  Stephen K Tyring
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

7.  (-)-Epigallocatechin-3-gallate induces Du145 prostate cancer cell death via downregulation of inhibitor of DNA binding 2, a dominant negative helix-loop-helix protein.

Authors:  Katherine L Luo; Jian-Hua Luo; Yan P Yu
Journal:  Cancer Sci       Date:  2009-11-06       Impact factor: 6.716

Review 8.  Cellular signaling perturbation by natural products.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong
Journal:  Cell Signal       Date:  2009-03-16       Impact factor: 4.315

Review 9.  Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

Authors:  H Yang; K R Landis-Piwowar; D Chen; V Milacic; Q P Dou
Journal:  Curr Protein Pept Sci       Date:  2008-06       Impact factor: 3.272

Review 10.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.